Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer
Autor: | Hidekazu Hirano, Hirokazu Shoji, Narikazu Boku, Natsuko Okita, Hironobu Hashimoto, Yoshitaka Honma, Masatoshi Sekiguchi, Ryo Otsuka, Masakazu Yamaguchi, Yoshinori Makino, Takako Yanai, Ken Kato, Atsuo Takashima, Satoru Iwasa |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Paclitaxel medicine.medical_treatment Antibodies Monoclonal Humanized Gastroenterology Ramucirumab 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Cumulative incidence Aged Retrospective Studies Cisplatin Aged 80 and over Chemotherapy business.industry Peripheral Nervous System Diseases Hematology General Medicine Middle Aged Discontinuation Oxaliplatin 030104 developmental biology Oncology Tolerability chemistry 030220 oncology & carcinogenesis Surgery Female business medicine.drug |
Zdroj: | International journal of clinical oncology. 25(4) |
ISSN: | 1437-7772 |
Popis: | Fluoropyrimidine plus platinum, followed by paclitaxel (PTX) plus ramucirumab is a recommended treatment strategy for advanced gastric cancer (AGC). We investigated how peripheral neuropathy (PN), induced by platinum in first-line chemotherapy, affected the tolerability of second-line chemotherapy with PTX (2nd-PTX). The subjects were AGC patients who received second-line chemotherapy with PTX (2nd-PTX) after the failure of platinum-based chemotherapy between March 2015 and June 2018. We retrospectively reviewed PN severity, and dose reduction and/or discontinuation due to PN during 2nd-PTX, and compared the cumulative incidence of grade 2 PN between the two groups according to first-line chemotherapy containing oxaliplatin (L-OHP) or cisplatin (CDDP). The L-OHP and CDDP groups consisted of 50 patients each. PN severity before 2nd-PTX was grade 1/2 in 46/12% of patients in the L-OHP group, and 100/0% in the CDDP group. The worst grades of chemotherapy-induced PN during 2nd-PTX were grades 1/2/3 in 40/34/14% of patients in the L-OHP group, and 36/18/0% in the CDDP group. Median time to grade 2 PN after starting second-PTX was 2.5 months in the L-OHP group and 8.6 months in the CDDP group (hazard ratio 3.34, p = 0.002). The frequencies of a PN-related dose reduction and/or discontinuation of PTX were 18% in the L-OHP group and 8% in the CDDP group (p = 0.234). The severity of PN and tolerability of 2nd-PTX may be affected by first-line chemotherapy with L-OHP or CDDP for AGC. |
Databáze: | OpenAIRE |
Externí odkaz: |